European panel recommends Avastin for type of ovarian cancer patients

Avastin, the world's best-selling cancer drug from Swiss drug maker Roche, received a positive opinion Friday from a European Union group to treat a subset of ovarian cancer patients. The Committee for Medicinal Products for Human Use, or CHMP, essentially recommended that EU authorities approve Avastin in combination with the chemotherapy agents carboplatin and gemcitabine to treat women with recurrent, platinum-sensitive ovarian cancer, the company said Friday.